Cancer – AREN1721: Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma Across All Age Groups
Condition or Therapy:
TFE/translocational renal cell carcinoma
Cancer and Blood Disorders
Study Number: AREN1721
What is the goal of this study?
This phase 2 trial studies how well axitinib and nivolumab works in treating patients with TFE/translocation renal cell carcinoma that cannot be removed by surgery or has spread to other places in the body.
Who can join the study?
This study may be a good fit for children and young adults who:
- are older than 12 months, and
- Have been diagnosed with translocation morphology renal cell carcinoma.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.